Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-10-19 00:00:00 ET · period of report 2022-10-17 · accession 0001209191-22-054088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-19 | 2022-10-17 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +2,800 | 45.1K | +7% | +$6,776 |
| DM | 2022-10-19 | 2022-10-17 | PCVX | Wassil Jim | COO | S - Sale+OE | $25.72 | -2,800 | 42.3K | -6% | -$72.0K |
| D | 2022-10-19 | 2022-10-17 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -2,800 | 221.9K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-17 | M | A | 2,800 | $2.42 | 45,144 | D | — | — | |
| 2 | Common | Common Stock | 2022-10-17 | S | D | 874 | $25.31 | 44,270 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $24.68 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2022-10-17 | S | D | 1,926 | $25.91 | 42,344 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $25.685 to $26.205. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Stock Option (right to buy) | 2022-10-17 | M | D | 2,800 | $0.00 | 221,926 | D | $2.42 · — to 2029-12-16 | 2,800 Common Stock | (F4) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |